Open AccessCHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Author(s) -
Reinhard Angermann,
Anna Huber,
Yvonne Nowosielski,
Stefan Salcher,
Thomas Gasser,
Christof Seifarth,
Martina Kralinger,
Claus Zehetner
Publication year - 2021
Publication title -
retina
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.24
H-Index - 120
eISSN - 1539-2864
pISSN - 0275-004X
DOI - 10.1097/iae.0000000000003344
Subject(s) - aflibercept , medicine , macular degeneration , vascular endothelial growth factor , vegf receptors , ophthalmology , gastroenterology , urology , bevacizumab , chemotherapy
To analyze and compare the effects of intravitreal brolucizumab versus aflibercept on systemic vascular endothelial growth factor (VEGF)-A levels in patients with neovascular age-related macular degeneration.